Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Sprouty2 limits intestinal tuft and goblet cell numbers through GSK3β-mediated restriction of epithelial IL-33

Abstract

Dynamic regulation of intestinal cell differentiation is crucial for both homeostasis and the response to injury or inflammation. Sprouty2, an intracellular signaling regulator, controls pathways including PI3K and MAPKs that are implicated in differentiation and are dysregulated in inflammatory bowel disease. Here, we ask whether Sprouty2 controls secretory cell differentiation and the response to colitis. We report that colonic epithelial Sprouty2 deletion leads to expanded tuft and goblet cell populations. Sprouty2 loss induces PI3K/Akt signaling, leading to GSK3β inhibition and epithelial interleukin (IL)-33 expression. In vivo, this results in increased stromal IL-13+ cells. IL-13 in turn induces tuft and goblet cell expansion in vitro and in vivo. Sprouty2 is downregulated by acute inflammation; this appears to be a protective response, as VillinCre;Sprouty2F/F mice are resistant to DSS colitis. In contrast, Sprouty2 is elevated in chronic colitis and in colons of inflammatory bowel disease patients, suggesting that this protective epithelial-stromal signaling mechanism is lost in disease.

Introduction

Tight control of secretory cell differentiation is crucial for maintaining a healthy intestinal epithelium. For example, secretory tuft and goblet cells perform defensive roles against disease by supporting tissue maintenance and repair and providing a physical mucus barrier against the external environment1,2,3, and defects in these cells predispose to or exacerbate barrier dysfunction and inflammation4,5. On the other hand, excessive secretory cell development at the expense of absorptive lineages could in theory also be detrimental. Like many elements of intestinal physiology, a careful balance in a Goldilocks zone is required. Furthermore, the optimal mix of lineages may change rapidly in the face of injury or inflammation6,7,8, requiring the organ to rapidly alter its cellular composition to deal with current conditions.

Despite the importance of tight, and apparently dynamic, regulation of secretory differentiation, relatively little is known about how this balance is maintained. What is clear is that intracellular signaling plays a major role. PI3K and MAPK signals rapidly alter the balance of secretory cell development9,10,11. Some of these pathways are dysregulated in inflammatory bowel disease (IBD), and defects in them likely play a key role in epithelial dysfunction during chronic inflammation12,13. However, the mechanisms by which diverse signals (MAPKs, PI3K/Akt, Wnts, etc.) are integrated and regulated in the gut are not well understood.

Sprouty2 is a widely expressed regulator and integrator of intracellular signaling downstream of receptor tyrosine kinases. It was originally identified as a critical player in branching morphogenesis in the developing mammalian lung14,15,16,17, and its ability to bind and inhibit Raf18,19 placed it as a regulator of the canonical MAPK cascade (i.e., Ras-Raf-MEK-ERK). Since then, docking sites on Sprouty2 for molecules such as the ubiquitin ligase Cbl20,21, the adapter protein Grb2 (ref. 22), Src22,23, and components of the PI3K pathway24,25 have been identified, pointing to a broader and more integrative role in controlling and shaping signaling. As these pathways are involved in the cellular differentiation and immune responses in various tissue types, we sought to determine the function of Sprouty2 in the colonic epithelium.

To address this question, we used coordinated in vivo (intestinal epithelial-specific Sprouty2 knockout mice) and in vitro (colonoid culture) approaches to study how Sprouty2 fine-tunes the intestinal environment by modulating epithelial function, cell differentiation, and cytokine production. We find that Sprouty2 is a key regulator of tuft and goblet cell census in the colon, through an epithelial–stromal circuit involving PI3K, GSK3β, IL-33, and IL-13. Furthermore, Sprouty2 expression was responsive to acute inflammatory stimuli, suggesting that it is a mediator of dynamic changes to secretory cell populations in response to acute challenge. While inflammatory cytokine-induced suppression of Sprouty2 was conserved in healthy human tissues, Sprouty2 levels were in contrast elevated in human IBD. Thus, loss of this mechanism potentially contributes to disease by removing a compensatory response to injury and inflammation.

Results

Sprouty2 is robustly expressed in the colonic epithelium but is repressed by inflammation

As a first step toward identifying the function of Sprouty2 in the gut, we analyzed its expression pattern. Spry2 was present throughout the intestinal tract, with highest levels in the colon (Fig. 1a). It was enriched in the epithelium, with low expression in the subepithelial space (Fig. 1b). As an integrator of extracellular stimuli, Sprouty2 expression is repressed by inflammatory challenge in airway epithelial cells26; to test if it is similarly regulated in the colon, we subjected mice to dextran sodium sulfate (DSS) colitis for 4 days to cause acute damage, followed by 3 days of recovery (Fig. 1c). Sprouty2 RNA and protein levels were significantly reduced by 3 days post DSS injury (Fig. 1d, e), correlating with elevated Tnf (Fig. 1d). In vitro, TNF inhibited SPRY2 expression in human colonic epithelial organoid cultures (colonoids), cultured human (HT-29) colonocytes (Fig. 1f), murine colonoids (Fig. 1g), and cultured mouse (YAMC) colonocytes (Fig. 1h, i). Collectively, these data show that Sprouty2 is an inflammation-regulated epithelial target both in vivo and in vitro.

Fig. 1: Sprouty2 is highly expressed in the colonic epithelium and repressed by inflammation.
figure1

a Expression of Spry2 was analyzed in tissue homogenates along the length of the intestinal tract by qPCR (n = 4 mice; **p < 0.01). b In situ analysis of murine distal colonic sections showed Spry2 is predominantly expressed within the epithelial compartment. Scale bar = 25 µm; representative of stains of three mice. c Mice were subjected to 3% DSS in drinking water for 4 days followed by 3 days chase to induce colitis and d distal colonic homogenates were analyzed by qPCR for Sprouty2 (n = 9 mice per group; ****p < 0.0001) and Tnf (n = 11 mice per group, ***p = 0.0003). e Western blot for Sprouty2 on colonic homogenate from water and DSS-treated mice (representative of four mice per group). f Primary human (n = 4 independent cultures derived from four surgical specimens; ***p = 0.0002) colonic epithelial colonoids, human colonic cells (HT-29; n = 5 independent experiments; ***p = 0.0003), g murine (n = 6 cultures derived from six mice; **p = 0.0018) colonoids, and h immortalized mouse colon cells (YAMC; n = 8 independent experiments; ****p < 0.0001) were treated with TNF (100 ng/ml) for 24 h and analyzed by qPCR for SPRY2 levels. i Western blot for Sprouty2 in TNF-treated YAMC cells after 24 h (representative of four independent experiments). Data in this figure are presented as mean ± SEM. Analyzed by a one-way ANOVA with Tukey post hoc test or d, fh two-sided t test.

Tuft and goblet cell numbers are increased in the colons of Spry2IEKO mice

To understand the functional outcome of inflammation-induced Sprouty2 repression in the colonic epithelium, we generated intestinal epithelial-specific Sprouty2 deletion mice (VillinCre;Spry2flox/flox, hereafter termed Spry2IEKO; Fig. 2a). Since the MAPK and PI3K cascades regulated by Sprouty2 are intimately involved in differentiation9,11, we analyzed lineage markers (Fig. 2b–f) and found a significant increase in tuft (Dclk1, Trpm5, and Il25) and goblet (Muc2 and Tff3) cell marker expression in colonic homogenates of Spry2IEKO mice compared to Cre-negative littermate controls. In contrast, markers for enteroendocrine (ChgA), stem (Lgr5, Lrig1), and absorptive (Car2, Aqp8) cells did not change, suggesting specificity in the response. To confirm that RNA changes correlated with increased tuft and goblet cell numbers, we stained colonic sections for Dclk1, chromogranin A, and Muc2 (Fig. 2g–i). Spry2IEKO mice showed an increase in the number of both tuft and goblet cells, but not enteroendocrine cells. The differential regulation of secretory cells suggests an additional modulator of secretory pathways may be required for enteroendocrine specification27. To test whether Spry2 deletion altered the epithelial cell life cycle, we analyzed proliferation and apoptosis in distal colon, but found no differences between Spry2IEKO mice and control littermates (Fig. 2j, k). We also observed no differences in crypt length (Fig. 2l).

Fig. 2: Loss of epithelial Sprouty2 results in expansion of colonic tuft and goblet cell numbers.
figure2

a Deletion of Sprouty2 in Spry2IEKO mice was confirmed by qPCR and western blot of colonic homogenates. b Tuft (Dclk1, Trpm5, and Il25), c enteroendocrine (Chga), d goblet (Muc2 and Tff3), e stem (Lgr5 and Lrig1), and f absorptive enterocyte (Car2 and Aqp8) markers were measured in Spry2IEKO colonic homogenates by qPCR. g Tuft (Dclk1+; in red), h enteroendocrine (ChgA+; in red), and i goblet (Muc2+; in red) cells were quantified by immunofluorescence staining of distal colonic sections. Green = E-cadherin. Scale bar = 25 µm. j Proliferation (Ki67+), k apoptosis (TUNEL+), and l crypt length were quantified in distal colons. Data are presented as mean ± SEM. Analyzed by two-sided t test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Exact p values where appropriate are as follows b Dclk1 p = 0.0065; Trpm5 p = 0.0203; Il25 p = 0.0046; d Muc2 p = 0.0124; Tff3 p = 0.0099; g p = 0.0002. Number of mice analyzed, from five independent litters, in each panel as follows: a 16 per group; b Dclk1 19 FF, 14 KO; Trpm5 16 FF, 12 KO; Il25 15 FF, 13 KO; c 14 FF, 9 KO; d Muc2 17 FF, 13 KO; Tff3 17 FF, 13 KO; e, f 14 FF, 9 KO; g 10 FF, 8 KO; h 14 FF, 8 KO; i 7 FF, 7 KO; and jl 7 FF, 6 KO.

Sprouty2 deletion induces colonic epithelial IL-33 expression

The intestinal epithelium is a potent producer of cytokines that shape epithelial and immune responses in the gut. IL-33 is a member of the IL-1 superfamily with reported expression in both the epithelium and mesenchyme. It is linked to secretory cell development, which may be a response mechanism to protect the epithelium from insult. However, the environmental and intracellular signals differentially regulating IL-33 expression in different cell types are not well understood. To test whether Sprouty2 might influence tuft and goblet cell expression through modulation of IL-33 expression, we first performed qPCR analysis on distal colonic homogenates. We observed a significant increase in Il33 expression in Spry2IEKO mice versus control littermates (Fig. 3a). IL-33 induction specifically in the epithelium was confirmed by ELISA on distal colonic epithelial scrapings (Fig. 3b). To test for IL-33 release, we cultured isolated distal colonic epithelia for 6 h. Conditioned media from these cultures showed elevated IL-33 release from Sprouty2-null cultures (Fig. 3c). Similar to the in vivo results, Il33 was durably elevated in passaged knockout colonoids (Fig. 3d), specifically demonstrating increased epithelial expression. Interestingly, while tuft and goblet cell markers were elevated in Sprouty2-null epithelia in vivo (Fig. 2), this was not the case in passaged colonoids (Fig. 3d), suggesting a requirement for an additional, extra-epithelial signal.

Fig. 3: Colonic epithelial IL-33 expression is increased in Spry2IEKO mice.
figure3

a Il33 expression was measured by qPCR in colonic homogenates from Spry2FF and Spry2IEKO mice (n = 17 FF, 13 KO; ***p = 0.0002). b IL-33 protein was measured in colonic epithelial scrapings by ELISA (n = 5 FF, 4 KO; *p = 0.0172). c Secreted IL-33 was measured in conditioned media from epithelial peels after 6 h incubation by ELISA (n = 3 per group; *p = 0.0314). d Expression of Spry2 (n = 11 FF, 9 KO cultures; ****p < 0.0001), Il33 (n = 11 cultures; *p = 0.0221), Dclk1 (n = 8 cultures), and Muc2 (n = 7 cultures) was assayed by qPCR in passaged colonoids generated from Spry2FF and Spry2IEKO mice. Il33, Dclk1, and Muc2 expression in Spry2IEKO is presented relative to Spry2FF mice (indicated by red dashed line n = 11 cultures). In figure, each colonoid culture was generated from a separate mouse and data are presented as mean ± SEM. Analyzed by two-sided t test.

Tuft and goblet cell expansion in Spry2IEKO mice requires stromal signals

In the intestine1,6,28, stomach29, and skin30 IL-33 can drive IL-13 release from type 2 innate lymphoid cells (ILC2s). We performed in situ analysis for Il13+ cells and found a significant increase in their numbers within colonic stromal tissue of Spry2IEKO mice (Fig. 4a). We also found elevated levels of IL-13 protein in distal colonic epithelial scrapings by ELISA (Fig. 4b). To further confirm ILC2 numbers, we stained sections for Gata3, a marker expressed by ILC2s31,32 and observed elevated numbers of Gata3+ cells within the colonic epithelium. Furthermore, we detected enrichment of an intestinal ILC2 signature31 by gene set enrichment analysis on RNA-sequencing results from colons of these mice (Fig. 4d).

Fig. 4: IL-33-driven tuft and goblet cell expansion requires stromal IL-13.
figure4

a Distal colonic sections from Spry2FF and Spry2IEKO mice were probed for Il13 by in situ RNAscope analysis and counted for IL-13+ cells per 100 crypts (dashed line around colonic crypt at base of epithelium); n = 7 FF, 6 KO mice; *p = 0.0301. Scale bar = 25 µm. b Epithelial scrapings from Spry2FF and Spry2IEKO mice were measured for IL-13 levels by ELISA; n = 5 per group; *p = 0.0338. c Number of Gata3+ cells was quantified in distal colonic tissue. Gata3 = red, E-cadherin = green; n = 3 per group; *p = 0.0409. Scale bar = 25 µm. d Gene set enrichment analysis (GSEA) using a published intestinal ILC2 gene signature from bulk tissue31 was performed on RNA sequencing of distal colonic homogenates; n = 6 per group. Colonoids generated from WT mice were treated with e IL-33 (100 ng/ml, n = 5 cultures per group) or f IL-13 (10 ng/ml, n = 8 cultures per group) for 24 h, and analyzed for tuft (Dclk1) and goblet cell (Muc2, Tff3) marker expression. Each colonoid culture was from a different mouse. *p < 0.05; **p < 0.01. g WT and IL-13−/− mice were i.p. injected with PBS or IL-33 for 4 days, and distal colonic expression of tuft cell markers (Dclk1, Trpm5, and Pou2f3) was assayed by qPCR, revealing a requirement for IL-13 in IL-33 mediated tuft cell induction in the colon; n = 7 WT + PBS, 8 WT + IL-33, 8 IL-13KO + PBS, and 10 IL-13KO + IL-33. *p < 0.05; **p < 0.01. Data are presented as mean ± SEM. Analyzed by af two-sided t test or g one-way ANOVA with Tukey post hoc test.

To test if tuft and goblet cell expansion is an epithelial-intrinsic response to IL-33 or in contrast requires IL-13, we treated colonoids from wild-type mice with these cytokines. Exogenous IL-33 was not sufficient to promote expression of tuft (Dclk1) or goblet (Muc2 and Tff3) cell markers in colonoids (Fig. 4e), while IL-13 robustly induced these genes (Fig. 4f). In vivo, we found that tuft cell marker induction in the colon by IL-33 injection did not occur in IL-13 KO mice (Fig. 4g), extending previous work demonstrating similar findings for goblet cells33. Together these results suggest an epithelial–stromal circuit in which Sprouty2 downregulation allows for IL-33 expression in the epithelium, promoting IL-13 release in the subepithelial cells which in turn signals back to the epithelium to alter cell differentiation patterns, consistent with a recent study on IL-33-driven ileal goblet cell hyperplasia33.

Increased ILC2 presence is frequently associated with activation of Th2 immunity (e.g., in response to Helminth infection). To test whether loss of epithelial Sprouty2 drives substantial changes in the baseline immune profile of the colon, we examined canonical cytokine markers for Th1, Th2, or Th17 immunity in RNA-sequencing data generated from distal colonic homogenates of Spry2FF and Spry2IEKO mice. We detected no significant differences between genotypes, suggesting the baseline immune profile is not highly altered by loss of Sprouty2 (Fig. 5a–c). These findings were confirmed by qPCR analysis in a subset of cytokine markers (Fig. 5d–f). As an ancillary approach to identifying changes in the immune cell landscape, we next used a computational approach to identifying specific changes in immune cell subsets within the colon. We applied the well-validated CIBERSORT algorithm34 to our dataset. This computational cell-type identification method estimates relative immune cell abundances from a mixed cell input, and has been previously validated for use in intestinal tissues35,36. Results from this analysis indicated no significant differences in relative abundance of major leukocyte and lymphocyte subtypes detectable with the immune gene set37 applied (Fig. 5g), suggesting loss of Sprouty2 does not broadly drive changes in the colonic immune profile, but is rather specific to ILC2s.

Fig. 5: Canonical markers of Th1, Th2, and Th17 immunity are unchanged in Spry2IEKO mice.
figure5

RNA sequencing was performed on distal colonic homogenates from Spry2FF and Spry2IEKO mice. ac Expression levels (as transcripts per million, TPM) of canonical Th1, Th2, and Th17 cytokines were compared between groups; n = 6 mice per group. df Expression of principal drivers of Th1, Th2, and Th17 immunity were confirmed by qPCR in a larger cohort of mice (Tnf, n = 16 FF, 12 KO; Il10; n = 12 FF, 9 KO; and Tgfb, n = 14 FF, 10 KO). g The relative abundance of immune cell subtypes was estimated in distal colons of Spry2FF and Spry2IEKO mice by CIBERSORT; n = 6 mice per group. Data are presented as mean ± SEM. Analyzed by two-sided t test.

Sprouty2 loss leads to GSK3β inhibition, thus promoting colonic IL-33 expression

To understand the precise signaling mechanisms through which Sprouty2 controls epithelial IL-33, we performed a screen for phosphorylated growth factor receptor signaling outputs on Spry2IEKO and Cre-negative Spry2FF littermates. This analysis showed increased serine 9 phosphorylation on the Wnt regulator, GSK3β, in Spry2IEKO mucosa, shown here by western blot on distal colonic lysates demonstrating elevated S9 GSK3β phosphorylation in Sprouty2-null colon (Fig. 6a). S9 is an Akt-mediated inhibitory phosphosite on GSK3β38 (see schematic in Fig. 6b), and western blot analysis for Ser473 phospho-Akt identified a significant increase in Spry2IEKO mice (Fig. 6c). Furthermore, hallmark gene set enrichment analysis on the RNA-sequencing data from distal colon showed elevated K-Ras signaling (which includes PI3K and PI3K targets) in Spry2IEKO mice (Fig. 6d). As GSK3β can regulate cytokine levels in some tissues, we asked whether it controls IL-33 expression in the colon and intestine. In both mouse colon epithelial cells (YAMC) and rat intestinal epithelial cells (IEC-6), inhibition of GSK3β using the specific inhibitor CHIR99021 resulted in increased Il33 levels (Fig. 6e, f). Levels of the epithelial-expressed cytokine Cxcl2 were unaltered, demonstrating this response was not a generalized cytokine regulation (Fig. 6e, f). Next, since Akt is negatively regulated by Sprouty2 (ref. 24) and is responsible for serine 9 phosphorylation on GSK3β38, we also hypothesized that Sprouty2 loss-driven Il33 induction is through PI3K/Akt. In YAMC and IEC-6 cells, Il33 levels were substantially reduced by PI3K/Akt inhibition (Fig. 6e, f). The same findings on Il33 were observed in primary colon epithelial culture using colonoids (Fig. 6g). Like IL-33 treatment, GSK3β inhibition was also unable to induce tuft and goblet cell markers in colonoids (Fig. 6h). Together these data suggest that Sprouty2 repression of PI3K/Akt signaling is permissive for GSK3β activity, and that a baseline inhibition of IL-33 is released when Sprouty2 is repressed by inflammation.

Fig. 6: Sprouty2 loss leads to GSK3β inhibition, thus promoting colonic IL-33 expression.
figure6

a Serine 9 phospho-GSK3β levels (**p = 0.0068) were measured in colonic homogenates from Spry2FF (FF) and Spry2IEKO mice (KO) by western blot. b Schematic of the Akt inhibitory phosphorylation of serine 9 on GSK3β. c Serine-473 phospho-Akt levels (*p = 0.0141) were measured in colonic homogenates from Spry2FF (FF) and Spry2IEKO mice (KO) by western blot. d Gene set enrichment analysis (GSEA) using the hallmark K-Ras gene signature was performed on RNA-sequencing results from distal colonic homogenates. Gene expression is defined in key where red indicates relative higher levels and blue indicates relative lower levels, per rank list metric in enrichment plot. e, f The effects of GSK3β inhibition (using CHIR99021, 3 µM) and/or PI3K/Akt inhibition (using LY294002, 10 µM) for 24 h on Il33 and Cxcl2 expression were measured in mouse colon (YAMC) cells, and rat intestinal epithelial (IEC-6) cells by qPCR. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. g Il33 levels were measured in GSK3β or PI3K/Akt inhibited murine colonoids by qPCR. **p < 0.01 versus VEH; #p < 0.05 versus LY. h Dclk1, Muc2, and Tff3 were measured in GSK3β inhibited murine colonoids by qPCR (presented as expression relative to vehicle treated group, indicated by dashed red line). In figure, each colonoid culture was generated from a separate mouse. Data are presented as mean ± SEM. Analyzed by one-way ANOVA with Tukey post hoc test or two-sided t test. Number of independent biological replicates for each dataset is: a n = 4 FF, 3 KO; c n = 4 per group; d n = 6 per group; e 13 independent experiments for Il33, VEH versus CHIR; 3 independent experiments for LY versus CHIR + LY; and for Cxcl2, VEH versus CHIR, n = 10 independent experiments. f Eight independent experiments for Il33, VEH versus CHIR; three independent experiments for LY versus CHIR + LY; for Cxcl2, seven independent experiments. In g, independent cultures for Il33, VEH, n = 10; CHIR, n = 10; LY, n = 6; and CHIR + LY, n = 10. In h, Dclk, n = 12 cultures; Muc2, n = 8 cultures; and Tff3, n = 8 cultures, (all compared to VEH n = 10).

Spry2IEKO mice are protected against DSS colitis

Tuft and goblet cells play important roles in protecting the colonic epithelium from damage, as demonstrated by spontaneous colitis in Muc2−/− mice4,39 and increased susceptibility to DSS colitis in Dclk1-deficient animals5,40. Furthermore, IL-33 ameliorates DSS colitis41,42. This suggests that Spry2IEKO mice, which have increased tuft and goblet cell numbers and elevated IL-33, might be protected from experimental colitis. To test this hypothesis, we subjected Spry2IEKO mice and control littermates to acute DSS (3% in drinking water for 4 days, followed by 3 days chase on standard water). Sprouty2 deletion protected mice from weight loss (Fig. 7a), led to improved histopathology scores (Fig. 7b), reduced fecal lipocalin-2 (Fig. 7c), reduced colon shortening (Fig. 7d), and lowered inflammatory cytokine expression (Fig. 7e) following DSS. Apoptosis as measured by TUNEL stain was also significantly reduced in Spry2IEKO colons (Fig. 7f). Notably, expression of the goblet cell marker Muc2 was elevated following DSS in the Spry2IEKO distal colons compared to wild type (Fig. 7h). Furthermore, since Lgr5+ stem cells can be lost in acute inflammatory injury, we measured stem cell markers in distal colon by qPCR, and found that expression of Lgr5 and Lrig1 were spared in mice with Sprouty2 deletion in comparison to wild type (Fig. 7g). In contrast, Bmi1, which marks reserve stem cells and/or reversion-capable progenitors, was not altered (Fig. 7g).

Fig. 7: Spry2IEKO mice are protected against DSS colitis.
figure7

Spry2FF and Spry2IEKO mice were given 3% DSS in drinking water for 4 days, followed by 3 days of plain drinking water to induce colitis. a Weights were measured daily; *p < 0.05; **p < 0.01. b Colonic sections were scored by a blinded pathologist; **p = 0.0099. c Fecal lipocalin-2, a marker of intestinal inflammation, was measured by ELISA; **p < 0.01. d Colon lengths were measured (p = 0.0002) and e expression of Il1b was assayed in distal colonic homogenates by qPCR between DSS-treated groups at day 7 (p = 0.0146). f Apoptosis rate in distal colon (p = 0.0001) was measured by TUNEL stain (green). Scale bar = 75 µm. Expression of g Lgr5 (p = 0.0212), Lrig1 (p = 0.0280), Bmi1, and h Muc2 (p = 0.0028) were analyzed by qPCR in distal colonic homogenates; colonic sections were subjected to immunofluorescence for Muc2 (red). Scale bar = 150 µm. i In wild-type (C57BL/6 J) mice subjected to 3% DSS for 4 days followed by 3 days of plain water, expression of Spry2 was analyzed in colonic homogenates by qPCR and j IL-33 levels were measured in epithelial scraping at 0, 2, 4, and 7 days by ELISA. *p < 0.05 versus day 0. k Goblet and tuft cell markers were analyzed in colonic homogenates by qPCR. **p < 0.01; ****p < 0.0001 versus day 0. In figure, data are presented as mean ± SEM. Analyzed by one-way ANOVA with Bonferroni post hoc test or two-sided t test. Number of mice analyzed, from five independent litters, in each panel as follows: a 11 WT, 16 KO; b 8 per group; c 4 FF CON, 3 KO CON, 4 FF DSS, 6 KO DSS; d 14 FF, 19 KO; e 9 FF, 14 KO; f 11 FF, 12 KO; g Lgr5 9 FF, 14 KO; Lrig1 and Bmi1 6 FF, 11 KO; h 9 FF, 14 KO; and ik n = 5 per time point.

To understand the temporal kinetics of Sprouty2 regulation by colitis and how it relates to IL-33 levels, we subjected wild-type C57/Bl6 mice to the same model of DSS colitis as above (3% in drinking water for 4 days, followed by 3 days chase on standard water). We found that Spry2 is lost in the distal colon as early as 2 days after starting DSS (Fig. 7i). Likewise, IL-33 protein (measured in epithelial scrapings) was elevated through day 4, though it returned to baseline by day 7 (Fig. 7j). Expression of goblet cell markers (Muc2 and Tff3) were significantly elevated at day 4. Tuft cell markers (Dclk1 and Trpm5) did not significantly change, though a trend toward increased expression was noted (Fig. 7k). These results suggest that in the presence of severe acute injury, loss of Sprouty2 tracks with increased IL-33 levels in the epithelium. However, either because of incomplete Spry2 suppression in the tissue or because of other complexities of the colitic tissue environment, these changes are not sustained in wild-type animals.

Sprouty2 levels are increased in human IBD

Our results in mice suggest that transient Sprouty2 downregulation by inflammation is a compensatory response to early damage signals (e.g., TNF). To consider whether this mechanism might be defective in IBD, we measured SPRY2 expression in colon endoscopic mucosal biopsies from pediatric IBD patients with active colonic inflammation and non-IBD controls. We found elevated SPRY2 expression in both ulcerative colitis and Crohn’s disease patients (Fig. 8a and Supplementary Table 1). These data are consistent with findings from Gamo et al. demonstrating elevated SPRY2 expression in adult IBD patients43. Furthermore, in our mucosal biopsy samples, SPRY2 levels were inversely correlated with IL33 expression (Fig. 8b). These data suggest that, while acute inflammation can downregulate Sprouty2 to promote IL-33 (Fig. 7), in chronic disease (where SPRY2 is elevated) this response is lost. To test whether inflammation-induced Spry2 expression might be lost with chronic stimulation, we challenged mouse colonocytes (YAMC cells) with continuous TNF exposure for 6 days. Acutely, this produced the expected loss of Spry2, but by 6 days of exposure this response was lost and Spry2 levels rebounded (Fig. 8c). This suggests that Spry2 downregulation by TNF becomes exhausted over time. Consistent with this, in the IL-10−/− chronic colitis model, Spry2 is elevated in colonic homogenates from adult animals with active inflammation versus young (pre-colitic) littermates (Fig. 8d), and these mice express reduced levels of tuft (Trpm5) and goblet cell (Muc2) markers in the distal colon. A failure to downregulate Sprouty2 in response to early damage signals may be a factor in IBD development (Fig. 8e).

Fig. 8: Sprouty2 is elevated in human IBD, and expression levels negatively correlate with tuft cell markers.
figure8

a Samples from patient mucosal biopsies from uninflamed non-IBD (n = 27), or inflamed ulcerative colitis (n = 8) and Crohn’s disease (n = 6), were analyzed for SPRY2 expression; *p < 0.05; **p < 0.01. Patient characteristics shown in Supplementary Table 1. b Correlation of SPRY2 and IL33 expression levels from IBD patient biopsies (qPCR, plotted as ddCt values). c YAMC cells treated chronically with 100 ng/ml TNF every 2 days for 6 days were measured by qPCR for Spry2 expression; n = 7 independent experiments. **p < 0.01 versus PBS. d Distal colonic homogenates from IL10−/− mice before onset of colitis (1 month of age; n = 5) and post-onset of chronic colitis (4–5 months of age; n = 10) were assayed by qPCR for Spry2 and markers of tuft and goblet cells. Spry2, *p = 0.0176; Trpm5, **p = 0.0022; Muc2, ****p < 0.0001. In figure, data are presented as mean ± SEM. Analyzed by one-way ANOVA with Dunnett post hoc test, Pearson correlation, or two-sided t test. e Proposed model of Sprouty2 regulation of epithelial IL-33 and secretory cell development in response to colonic inflammation: Acute inflammation represses Sprouty2 expression in the epithelium. This removes basal inhibition on PI3K/Akt, leading to Akt-mediated inhibition of GSK3β, promoting epithelial IL-33 expression. Epithelial-produced IL-33 induces IL-13 in the stroma, which in turn signals back to the epithelium to promote tuft and goblet cell expansion as a compensatory mechanism to limit acute inflammation and promote injury resolution. Loss of this dynamic differentiation mechanism in the setting of chronic inflammation might potentiate disease severity.

Discussion

Maintenance of homeostasis and effective responses to injury in the colonic epithelium require a well-regulated balance of different epithelial cell types, including stem, absorptive, and secretory cells. Epithelial-, stromal-, and immune-derived factors direct the development of these cell types44,45,46,47,48. However, the precise mechanisms that integrate these signals in the local environment to alter the cellular composition and function of the epithelium are incompletely understood.

In this study, we sought to define the role of Sprouty2 in controlling these processes. Growth factor receptor-initiated signaling, including PI3K and MAPK cascades, is indispensable for intestinal homeostasis49 and directs intestinal epithelial cell development and differentiation9,11,50. Major receptor tyrosine kinase families, such as the ErbBs and fibroblast growth factor (FGF) receptors, together with their cognate growth factor ligands, activate these cascades. In many cases, administration of the ligands (e.g., NRG1, EGF, and FGF10) alters epithelial cell differentiation and protects against injury or inflammation10,51. Sprouty2 can negatively regulate PI3K and MAPK cascades, and is itself regulated by growth factor signals22,26, typically induced as a negative feedback inhibitor to keep FGF, EGF, and other signals in check. Here, we show that it is also repressed by acute inflammation both in vitro and in vivo, and thus may play a role in regulating the colonic response to inflammation and injury. As Sprouty2 serves as an integrator and negative regulator of growth factor-induced pathways, it would be predicted that acute downregulation may exert influence on cell development and differentiation, similar to that of activating FGF receptors or ErbBs.

The use of intestinal epithelial-specific Sprouty2 deleted mice (Spry2IEKO) allowed us to isolate the effects of Sprouty2 loss from the broader inflammatory milieu of colitis, thus permitting us to directly test its function. Spry2IEKO mice showed increased numbers of secretory tuft and goblet cells, but not enteroendocrine cells or absorptive enterocytes. We speculate this induction may be a compensatory skewing toward cell types that are protective in mouse models of colitis4,5,52 and in patients with IBD53. Under this scenario, Sprouty2 is constitutively expressed in homeostasis, but is repressed by a danger signal (e.g., TNF) to enable a rapid response to insult. In acute experimental colitis, we observed loss of Spry2 rapidly during the injury phase (Fig. 7), which correlated with increased IL-33 levels. Subsequently, however, Spry2 levels remained low while the increased IL-33 was not sustained. We speculate this may be due in part to the aggressive Th1-skewed immune responses following DSS injury. This environment promotes a complex and evolving set of signals that appear to eventually overcome Sprouty2’s effects on IL-33 and IL-33’s role in secretory cell differentiation. Future work with a model where Sprouty2 is constitutively expressed during inflammation will allow us to address the important question of whether failure to downregulate contributes to worsened disease.

To identify downstream mediators driving the effect of Sprouty2 loss in unchallenged mice, we screened for factors known to skew cells along the secretory lineage. This led to the finding that Sprouty2 deletion induces IL-33 production in colonic epithelial cells. IL-33 is expressed by epithelial, stromal, and immune cells, though in homeostasis epithelial expression is normally low54,55. IL-33 regulation has predominantly been studied in immune cells56 and control of its expression in the intestinal epithelial compartment is not well understood. It has documented roles as a nuclear alarmin and an intracellular regulator of gene function, as well as potentially serving as a traditional secreted cytokine57. We found that Sprouty2-regulated IL-33 (Fig. 3) initiated an epithelial–stromal circuit (Fig. 4), and was enriched in media from Sprouty2-null cultured colonic epithelia (Fig. 3), suggesting that it is the secreted IL-33 form functioning here. Furthermore, Il33 was constitutively elevated in these mice and in Sprouty2-null colonoids, despite no injury markers (epithelial apoptosis or crypt shortening) at baseline (Fig. 2), suggesting that Spry2 downregulation is a compensatory, downstream response to injury rather than a contributor to it.

Interestingly, while colons from Spry2IEKO mice had a robust phenotype, this was not the case in the small intestine. The underlying mechanism is not entirely clear, but we speculate that the significantly lower baseline Sprouty2 levels in the small intestine (versus colon; Fig. 1) may already be past the signaling threshold to trigger the changes seen in the Spry2IEKO colon. Alternatively, additional regulatory mechanisms or compensation may be active in the small intestine. Future studies will address possible roles of Sprouty2 in the small intestine.

The role of IL-33 in colonic disease is controversial, as some studies suggest it is pathogenic58,59 while others have found it is associated with improved outcomes in colitis41,42. These different results likely depend on the cellular source of IL-33 and timing of when the cytokine is expressed in the course of disease60. Our data suggest that when IL-33 is expressed in the epithelium prior to the onset of disease, it conditions the epithelium against future insult (such as the chemical damage in DSS colitis). Using colonoids from Spry2IEKO and littermate controls, we show that epithelial loss of Sprouty2 directly regulates epithelial IL-33 expression and its impact on secretory cell differentiation is due to extra-epithelial interactions of the cytokine. In addition to promoting intestinal secretory differentiation, IL-33 can induce colonic epithelial wound healing via mir-320 induction41. Thus Sprouty2 regulation of IL-33 would be expected to have epithelial-intrinsic pro-repair effects in addition to the protective pro-secretory priming. Indeed, we find that siRNA knockdown of Spry2 in YAMC cells accelerates restitution in a scratch wound assay (Supplementary Fig. 2), consistent with suppression of restitution in IEC-6 cells by Sprouty2 overexpression61. Though this current study is focused on the epithelial–mesenchymal crosstalk effects on secretory differentiation stemming from Sprouty2 deletion, in future studies it will be important to also understand the cell-intrinsic changes brought about by Sprouty2 presence or absence.

While elevated epithelial IL-33 was maintained in Spry2IEKO colonoids following passage, tuft and goblet cell lineage markers were not. Furthermore, exogenous IL-33 did not induce tuft or goblet cell markers. This suggests IL-33 does not promote secretory differentiation by direct epithelial-intrinsic signaling, but rather requires interaction with stromal or recruited cells. Recent work has shown that IL-33 can activate innate lymphoid cells to produce IL-13 (refs. 57,62). Waddell et al. demonstrated that this cytokine then reciprocally acts on the intestinal epithelium to promote goblet cell expansion33. Consistent with this, we found elevated numbers of IL-13+ cells in Spry2IEKO colons; furthermore, IL-13 but not IL-33 induced tuft and goblet cell markers in wild-type colonoids. Importantly, we also confirmed a requirement for IL-13 by treating IL-13 KO and WT mice with IL-33, showing induction of tuft and goblet markers only in WT mice.

Given the induction in IL-33 and tuft and goblet cells in Spry2IEKO mice, it was surprising to not see a coordinate elevation in enteroendocrine cells on the same secretory lineage. Previous work in an IL-33 overexpression model suggested IL-33 mediated elevations in secretory populations included enteroendocrine cells63. However the lack of such induction in our model suggests additional variables including environmental factors (e.g., mouse genetics and microbiota), or Sprouty2 signaling modulation may play a role in specific differentiation of cell types in the secretory lineage.

In this study, we have detailed a Sprouty2-regulated intracellular signaling pathway in the colonic epithelium that influences secretory differentiation. Spry2IEKO mice had elevated levels of Akt activation and phosphorylation of the inhibitory serine 9 on GSK3β. Akt mediates this phosphorylation site38. This suggests a model where TNF-induced loss of Sprouty2 releases baseline inhibition on Akt signaling, allowing for serine 9 phosphorylation on GSK3β and induction of IL-33. Akt activation by Sprouty2 loss may result from removal of direct inhibition of the PI3K cascade, as Sprouty2 can bind and inactivate components of this pathway24,25. Alternatively, gene set enrichment analysis of our RNA-sequencing dataset indicates an upregulation of K-Ras signaling in Spry2IEKO colons (Fig. 6), which could also lead to increased signaling through PI3K-Akt. Future molecular studies are necessary to determine whether these effects encompass any direct actions of Sprouty2 on GSKβ, or strictly are a result of regulating intermediates, such as PI3K. In either case, for IL-33 induction, the pathway converges on GSK3β as demonstrated by the effects of CHIR99021 and LY294002 on colon cells (Fig. 6). Each inhibitor alone regulates Il33 expression; however, the combined result (attenuation of CHIR99021’s effect by PI3K blockade) is likely due to the mechanism of GSK3β regulation, which involves inhibition by phosphorylation on Ser9 by Akt. Since CHIR99021 serves as an ATP binding competitor for GSK3β rather than a downstream interrupter of signaling, phospho-Ser9 and CHIR99021 should cooperate or synergize to yield full inhibition. Thus, we hypothesize that full inactivation of GSK3β requires Akt blockade and is not completely achieved with CHIR99021 alone at concentrations that are specific for GSK3β. Therefore, only limited (but detectable) Il33 induction occurs with CHIR99021 when Akt is off.

Our results might indicate a role for Wnt signaling in the control of colonic IL-33, though it should be noted that GSK3β could work through other targets, and thus a Wnt connection will have to be formally tested in future studies. GSK3β and Wnt signaling are known to influence the balance of secretory cells in the intestine64, and our work reveals Sprouty2 as an upstream regulator controlled by inflammation and links this pathway to induction of IL-33 (Fig. 6). Previous reports have found that IL-33 influences Akt signaling65. However, the impact of PI3K/Akt in control of IL-33 in intestinal tissues has not previously been tested. In accord with Ivanov et al. showing that Akt promotes IL-33 signaling in human fibroblasts66, we found that inhibition of the PI3K/Akt cascade repressed basal IL-33 levels from the colonic epithelium. We cannot formally exclude the possibility that altered GSK3β signaling in Spry2IEKO mice also provides feedback to Akt to heighten IL-33 production, but at minimum our in vitro studies do show that IL-33 is regulated by PI3K.

The epithelial switches regulating the IL-33 production in the colonic epithelium, both at homeostasis and in the context of inflammation, are not well understood. Here, we have identified Sprouty2 as an integrator of extracellular stimuli (i.e., TNF) that modulates downstream signaling pathways controlling epithelial IL-33, and thus tuft and goblet cell specification. Tuft cells regulate an inflammatory circuit when activated by parasitic infection1, and both tuft and goblet cells protect against colitis in mice4,5,40. Furthermore, when these cell types are genetically targeted in mice, experimental colitis is exacerbated. Together these observations suggest that the Sprouty2 circuit described here might be compromised in IBD, a possibility supported by our data showing a significant increase in SPRY2 in colonic specimens from IBD patients. As some IBD patients with elevated type 2 immune response signatures (such as IL-13) have better outcomes53, an important next step will be to understand if Sprouty2 expression or its regulation by TNF is a valid biomarker for IBD severity.

Crohn’s disease and ulcerative colitis are in broad terms characterized by inappropriate or imbalanced activation of Th1 or Th2 immune responses. Prior work has suggested that skewing the immune system through early exposure to parasitic infection can alter the immune tone of the intestine and promote an epithelial composition that may be protective against IBD development67,68,69. Our findings suggest that priming an epithelium to an enhanced secretory tone (by deletion of Sprouty2) limits colitis severity. Interestingly however, we did not detect large scale activation of Th1, Th2, or Th17 immunity in the colons of Sprouty2 mice at baseline (Fig. 5). These findings suggest that, prior to insult, the epithelial–mesenchymal loop regulated by Sprouty2 remodels secretory differentiation without substantively altering immune function beyond ILC2s. It is intriguing to speculate that loss of Sprouty2 may shape the immune response once injury is onset, but due to the fact that elevated tuft and goblet cells are observed prior to injury, and would be predicted to suppress damage, we are unable to dissect primary effects on evolving immune responses versus secondary effects of epithelial-based protection under the current model.

Elevated Sprouty2 in IBD was an unexpected finding, as mucosal biopsies from ulcerative colitis patients (and to a lesser extent Crohn’s disease) can in some studies express elevated IL-33 (ref. 70). However, most biopsy samples contain epithelial, mesenchymal, and immune cells, making determination of the IL-33 source in these studies unclear, whereas Sprouty2 is primarily epithelial. Furthermore, the clinical sample set used here was small. Despite this, we observed a significant negative correlation between SPRY2 and IL33 levels in mucosal IBD biopsies. As IL-33 may be protective in human IBD, expanded studies correlating Sprouty2, IL-33, and colitis outcomes will be important to pursue to determine whether SPRY2 acts as a biomarker for disease severity. Longitudinal studies to correlate SPRY2 expression with tuft and goblet cell markers, and IBD outcomes will be an important step to test our proposed model in patients. It should be noted that these findings are only correlative, and the actual impact of IL-33 on colonic regulation depends on a number of variables. The source, processing (mature versus full-length forms), and localization of IL-33 within the colon likely play key roles in determining the outcome of its effects on tuft and goblet cell development. Specifically in this study, we have found that elevated epithelial IL-33 appears to be protective by directing an epithelial–mesenchymal signaling loop that expands tuft and goblet populations.

While it might seem surprising that SPRY2 levels are elevated in IBD when they are suppressed in DSS colitis, our data with multiple models suggest that inhibition of Sprouty2 is lost in chronic inflammation. In acute settings, regardless of organism (TNF treatment of either human or mouse epithelia, DSS colitis in the mouse), Sprouty2 levels are suppressed (Figs. 1 and 7). In contrast, in chronic settings (long-term TNF exposure in vitro, IL-10 null mice, and human IBD), this suppression is lost (Fig. 8). This suggests that the apparent discrepancy in DSS colitis versus human IBD is not a species issue (for example, cells from both mice and humans downregulate Sprouty2 in response to TNF), but rather a question of acute signals that are exhausted over time. However, we do not know whether distinct signaling outcomes occur by altered Sprouty2 expression in the setting of chronic inflammation where competing factors may influence cytokine response and secretory cell differentiation. We cannot exclude the possibility that the complex immune environment in colitis may also activate adaptive immune responses that promote Sprouty2 expression, but we were not able to identify such factors in the current study.

In summary, we have demonstrated that Sprouty2 is an inflammation-responsive protein in the colonic epithelium that maintains a cytokine circuit to control tuft and goblet cell numbers. This represents a way in which the epithelium regulates Akt and GSK3β signaling to produce IL-33, and thus alter the composition of the epithelial barrier in a manner that attenuates colonic inflammation.

Methods

Study approval

All animal use and experiments received ethical approval, and were monitored by the Children’s Hospital Los Angeles Institutional Animal Care and Use Committee (Animal Welfare Assurance #A3276-01) or the Cincinnati Children’s Hospital Medical Center Institutional Animal Care and Use Committee (Animal Welfare Assurance #A3108-01). All studies complied with relevant ethical regulations for animal testing and research. Mice were housed under standard conditions with ad libitum water and chow access in the AAALAC-accredited animal care facilities at Children’s Hospital Los Angeles or Cincinnati Children’s Hospital Medical Center. Mice were exposed to a half-day light cycle and temperature and humidity-controlled environment. Human tissue was collected after receiving ethical approval for studies and written informed consent was obtained from patients’ parent or legal guardian, under approved Institutional Review Board CCI-13-00287 and CCI-09-00093 at Children’s Hospital Los Angeles. Human studies were conducted in accordance with the criteria set by the Declaration of Helsinki.

Animal experiments

C57Bl/6 mice were obtained from Jackson Laboratory and used at age 8–10 weeks for experiments. Both male and female mice were used. Mice with an intestinal epithelial-specific deletion of Sprouty2 (VillinCre;Spry2flox/flox) were generated by crossing VillinCre (9 kb villin promoter construct) animals71 with mice harboring loxP-flanked Spry2 (Spry2flox/flox). VillinCre;Spry2flox/flox and Spry2flox/flox littermate controls aged 8–10 weeks were used for experiments. IL-13−/− mice and BALB/c controls aged 6–12 weeks were given daily i.p. injections of 0.4 µg rIL-33 for 4 days33. For acute colitis, mice were given 3% (w/v) DSS in drinking water for 4 days, followed by 3 days of plain drinking water. Analysis of colonic homogenates, epithelial scrapings, or epithelial peelings are described in figure legends, as appropriate.

Real-time PCR

RNA from cells and tissue was collected using on-column RNA isolation and purification (OMEGA Biotek), and cDNA generated with a high-capacity cDNA reverse transcriptase kit (Applied Biosystems, 4368814). Quantitative analysis of expression was performed using TaqMan assays (Supplementary Table 2) on an Applied Biosystems StepOne thermocycler. Fold change was calculated using the 2−ΔΔCt method. Results are expressed as average fold change in gene expression relative to control or nontreatment group using Hprt or Cdh1 as the reference gene, as appropriate.

RNAScope in situ hybridization

Distal colonic sections were probed using RNAScope probes Mm-Spry2 (Advanced Cell Diagnostics, #425061) or Mm-Il13 (Advanced Cell Diagnostics, #312291), using the RNAScope 2.5 HD Detection system (Advanced Cell Diagnostics, #322310) according to manufacturer-provided protocol.

Western blotting and proteome profiler

Protein lysates from cells and tissue were collected and lysed in RIPA buffer with Halt Protease inhibitor cocktail (Thermo Scientific, #1861278), and phosphatase inhibitor cocktails 2 and 3 (Sigma, P5726 and P0044)72. Protein concentration was determined by DC protein assay (Bio-Rad, #500). For proteome profiling, samples were analyzed according to manufacturer instructions using the Phospho-MAPK Array (R&D Systems, #893909). For western blots, 30 μg protein/condition were separated by SDS–PAGE (Thermo Scientific, NW0412A) and transferred to nitrocellulose membrane. Membranes were blocked with 5% milk and probed with 1:1000 Sprouty2 (Sigma, #AV50523) overnight at 4 °C, 1:1000 total and phospho-GSK3beta (S9; Cell Signaling, #12456 and #5558, respectively), 1:1000 total and phospho-Akt (S473; Cell Signaling, #2920 and #4060, respectively), or 1:10,000 mouse anti-Actin (Sigma, A1978) for 1 h at room temperature, followed by 1:20,000 IRDye-conjugated donkey anti-rabbit (LI-COR, #926-68023) and donkey anti-mouse (LI-COR, #926-32212) for 1 h at room temperature and quantification on an Odyssey imager (LI-COR) with Image Studio 4.0. Original scans are included in the source data file.

ELISA

Fecal lipocalin-2 levels in distal colon fecal contents were analyzed using Mouse Lipocalin-2 DuoSet ELISA (R&D Systems, DY1857) according to manufacturer-provided instructions. IL-13 and IL-33 levels in distal colonic epithelial scrapings or IL-33 in conditioned media from cultures of peeled distal colonic epithelium were analyzed using Mouse IL-13 DuoSet ELISA (R&D Systems, DY413) or Mouse IL-33 DuoSet ELISA (R&D Systems, DY3626) according to manufacturer instructions.

Cell lines and colonoids

For in vitro experiments, immortalized young adult mouse colon (YAMC) cells, immortalized rat small intestinal cells (IEC-6), and human colon cancer cells (HT-29) were grown to 90% confluency before use in experiments. Colonoids were generated and passaged from mouse colon and human colon using previously established protocols as follows9,73,74. Crypts were isolated by incubation of tissue in chelation buffer (2 mM EDTA and 43.4 mM sucrose in D-PBS) followed by shaking. Crypts were embedded in Matrigel (BD Biosciences), then overlaid with growth media for mouse (advanced DMEM/F12 [Invitrogen, #12634-010] supplemented with 2 mM GlutaMax [Invitrogen, 25030-081], 10 mM HEPES [Sigma, H0887], 1× Pen–Strep [Invitrogen, 15140-122], 1× N2 supplement [Invitrogen, #17502048], 1× B27 supplement [Invitrogen, 17504044], 10% R‐spondin conditioned media [from modified HEK-293T cell line generated by Dr. Jeffrey Whitsett at Cincinnati Children’s Hospital Medical Center], 100 ng/ml mNoggin [PeproTech, 250-38], 50 ng/ml mEGF [PeproTech, 315-09], and 3 µM CHIR99021 [PeproTech, 2520691]) or human (advanced DMEM/F12 supplemented with 2 mM GlutaMax, 10 mM HEPES, 1× Pen–Strep, 1× N2 supplement, 1× B27 supplement, 10% R‐spondin CM, 100 ng/ml hNoggin [Peprotech, #120-10X], 50 ng/ml hEGF [Invitrogen, #PHG0311], 500 nM LY-2157299 [AxonMedChem, #1491], 10 µM SB-202190 [Sigma, #S7067], 50 U/ml Gentamycin [Invitrogen, 15710064], and 0.25 µg/ml amphotericin B [Invitrogen, 109434]). Cultures were passaged every 7–10 days. Cultures were starved in basal medium (advanced DMEM/F12 supplemented with 2 mM GlutaMax, 10 mM HEPES, 1× Pen–Strep, 1× N2 supplement, and 1× B27 supplement) then treated with the indicated concentrations of murine TNF (Peprotech, #315-01), human TNF (Peprotech, #300-01), mouse IL-33 (Peprotech, #210-33), or mouse IL-13 (Peprotech, #210-13) for the time specified before collection.

Immunofluorescence staining

Distal colon sections (5 µm), from tissue fixed with 4% formaldehyde overnight and paraffin embedded, were dewaxed and blocked with 10% goat serum for 1 h at room temperature. This was followed by incubation with primary antibody against DCLK1 (Abgent, #AP7219B, 1:100), ChgA (ImmunoStar, #20085, 1:200), Muc2 (Santa Cruz, sc-15334, 1:1000), Gata3 (Cell Signal, #5852, 1:200), Ki67 (Thermofisher, #RM-9106, 1:200), or E-cadherin (BD Biosciences, #610181, 1:500) overnight at 4 °C. Cells were washed and incubated with secondary anti-mouse Alexa Fluor-488 (Life Technologies, #A11029, 1:1000) or anti-rabbit Alexa Fluor-546 (Life Technologies, #A11035, 1:1000) for 1 h at room temperature followed by mounting with Vectashield mounting media including DAPI (Vector Labs, H-1500). TUNEL stain (Roche, #11684795910) was performed according to manufacturer instructions75 on distal colonic sections from DSS-treated mice. Imaging was performed on a ZEISS 710 confocal system using Zen 2009 software.

Human tissue

Colonic tissues from endoscopic biopsies (for SPRY2 expression analysis) or gross surgical specimens (for colonoid generation) were obtained from pediatric patients either with or without IBD at Children’s Hospital Los Angeles. Samples were placed immediately in RNALater (Thermo Fisher Scientific, AM7021) or used for colonoid generation.

RNA sequencing and analysis

RNA isolated from distal colonic homogenates (from six Sprouty2FF and six Sprouty2IEKO littermates) were barcoded using Illumina index primers and sequenced on a NextSeq machine to obtain single-ended reads of 75 bp length to a depth of ~10 M reads/sample by SeqMatic LLC (San Francisco, CA). FASTQ files were pseudoaligned using kallisto76 to the mouse transcriptome to obtain transcript per million abundance estimates. To compare pathway enrichment, transcript abundances were summed to obtain a per-gene expression value, which was then input into GSEA 4.1.0 (ref. 77). Enrichment of the KRAS pathway was identified using the Hallmark database of targets78. Specific analysis for enrichment of ILC2 markers was performed using the GSEA algorithm against a previously identified ILC2 gene set profile enriched in intestinal tissue31 For immune cell estimation in colonic tissue, gene expression data (with HUGO gene symbols) were submitted to the CIBERSORT portal (http://cibersort.stanford.edu) and processed, using the LM22 signature gene file at 100 permutations34. Results were standardized as relative abundance of the total predicted immune cell populations.

Statistics

Statistical analyses and plots were generated using Prism 6 (GraphPad Software). Mean ± SEM is depicted in dot and bar graphs. All data points (dots) on plots represent biological replicates. Student’s two-sided t test or one-way ANOVA with Tukey, Dunnett, or Bonferroni post hoc test to correct for multiple comparisons were used to determine statistical differences, as indicated in figure legends. Statistical significance was assigned to p < 0.05, and indicated in figure legends.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

RNA-sequencing data for the results presented in Figs. 46 are freely and publicly available through the NCBI Gene Expression Omnibus; the accession number is GSE160854. The authors declare that all other data supporting the findings of this study are available from the corresponding author upon reasonable request. Source data are provided with this paper.

References

  1. 1.

    Gerbe, F. et al. Intestinal epithelial tuft cells initiate type 2 mucosal immunity to helminth parasites. Nature 529, 226–230 (2016).

    ADS  CAS  PubMed  Article  Google Scholar 

  2. 2.

    Tytgat, K. M. A. J. et al. Biosynthesis of human colonic mucin: Muc2 is the prominent secretory mucin. Gastroenterology 107, 1352–1363 (1994).

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Artis, D. et al. RELM /FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proc. Natl. Acad. Sci. USA 101, 13596–13600 (2004).

  4. 4.

    Van der Sluis, M. et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131, 117–129 (2006).

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    May, R. et al. Brief report: Dclk1 deletion in tuft cells results in impaired epithelial repair after radiation injury. Stem Cells 32, 822–827 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Howitt, M. R. et al. Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut. Science 351, 1329–1333 (2016).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Renes, I. B. et al. Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression. Int. J. Colorectal Dis. 17, 317–326 (2002).

    PubMed  Article  Google Scholar 

  8. 8.

    Renes, I. B. et al. Alterations in Muc2 biosynthesis and secretion during dextran sulfate sodium-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G382–G389 (2002).

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Almohazey, D. et al. The ErbB3 receptor tyrosine kinase negatively regulates Paneth cells by PI3K-dependent suppression of Atoh1. Cell Death Differ. 24, 855–865 (2017).

  10. 10.

    Al Alam, D. et al. Fibroblast growth factor 10 alters the balance between goblet and Paneth cells in the adult mouse small intestine. Am. J. Physiol. Liver Physiol. 308, G678–G690 (2015).

    CAS  Google Scholar 

  11. 11.

    Heuberger, J. et al. Shp2/MAPK signaling controls goblet/paneth cell fate decisions in the intestine. Proc. Natl Acad. Sci. USA 111, 3472–3477 (2014).

    ADS  CAS  PubMed  Article  Google Scholar 

  12. 12.

    Edelblum, K. L. et al. Raf protects against colitis by promoting mouse colon epithelial cell survival through NF-κB. Gastroenterology 135, 539–551.e3 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Edelblum, K. L. et al. TNFR1 promotes tumor necrosis factor-mediated mouse colon epithelial cell survival through RAF activation of NF-kappaB. J. Biol. Chem. 283, 29485–29494 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Mailleux, A. A. et al. Evidence that SPROUTY2 functions as an inhibitor of mouse embryonic lung growth and morphogenesis. Mech. Dev. 102, 81–94 (2001).

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    de Maximy, A. A. et al. Cloning and expression pattern of a mouse homologue of drosophila Sprouty in the mouse embryo. Mech. Dev. 81, 213–216 (1999).

    PubMed  Article  Google Scholar 

  16. 16.

    Tefft, J. D. et al. Conserved function of mSpry-2, a murine homolog of Drosophila Sprouty, which negatively modulates respiratory organogenesis. Curr. Biol. 9, 219–222 (1999).

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y. & Krasnow, M. A. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 92, 253–263 (1998).

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Yusoff, P. et al. Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. J. Biol. Chem. 277, 3195–3201 (2002).

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Gross, I., Bassit, B., Benezra, M. & Licht, J. D. Mammalian Sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J. Biol. Chem. 276, 46460–46468 (2001).

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Fong, C. W. et al. Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function. J. Biol. Chem. 278, 33456–33464 (2003).

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Feng, Y.-H. et al. Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. Cancer Sci. 101, 2033–2038 (2010).

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Hanafusa, H., Torii, S., Yasunaga, T. & Nishida, E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol. 4, 850–858 (2002).

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Lao, D.-H. et al. A Src homology 3-binding sequence on the C terminus of Sprouty2 is necessary for inhibition of the Ras/ERK pathway downstream of fibroblast growth factor receptor stimulation. J. Biol. Chem. 281, 29993–30000 (2006).

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Edwin, F., Singh, R., Endersby, R., Baker, S. J. & Patel, T. B. The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J. Biol. Chem. 281, 4816–4822 (2006).

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Gao, M. et al. SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Mol. Med. 4, 776–790 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Ding, W. & Warburton, D. Down-regulation of Sprouty2 via p38 MAPK plays a key role in the induction of cellular apoptosis by tumor necrosis factor-alpha. Biochem. Biophys. Res. Commun. 375, 460–464 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Gracz, A. D. et al. Sox4 promotes Atoh1-independent intestinal secretory differentiation toward tuft and enteroendocrine fates. Gastroenterology 155, 1508–1523.e10 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    von Moltke, J., Ji, M., Liang, H.-E. & Locksley, R. M. Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. Nature 529, 221–225 (2016).

    ADS  Article  CAS  Google Scholar 

  29. 29.

    Petersen, C. P. et al. A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut 67, 805–817 (2018).

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Rak, G. D. et al. IL-33-dependent group 2 innate lymphoid cells promote cutaneous wound healing. J. Investig. Dermatol. 136, 487–496 (2016).

  31. 31.

    Robinette, M. L. et al. Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat. Immunol. 16, 306–317 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Suffiotti, M., Carmona, S. J., Jandus, C. & Gfeller, D. Identification of innate lymphoid cells in single-cell RNA-Seq data. Immunogenetics 69, 439–450 (2017).

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Waddell, A., Vallance, J. E., Hummel, A., Alenghat, T. & Rosen, M. J. IL-33 induces murine intestinal goblet cell differentiation indirectly via innate lymphoid cell IL-13 secretion. J. Immunol. 202, 598–607 (2019).

  34. 34.

    Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015).

  35. 35.

    Penrose, H. M. et al. Loss of forkhead box O3 facilitates inflammatory colon cancer: transcriptome profiling of the immune landscape and novel targets. CMGH 7, 391–408 (2019).

  36. 36.

    Hegazy, A. N. et al. Circulating and tissue-resident CD4 + T cells with reactivity to intestinal microbiota are abundant in healthy individuals and function is altered during inflammation. Gastroenterology 153, 1320–1337 (2017).

  37. 37.

    Abbas, A. R., Wolslegel, K., Seshasayee, D., Modrusan, Z. & Clark, H. F. Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS ONE 4, e6098 (2009).

  38. 38.

    Zhang, F., Phiel, C. J., Spece, L., Gurvich, N. & Klein, P. S. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J. Biol. Chem. 278, 33067–33077 (2003).

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Velcich, A. et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295, 1726–1729 (2002).

    ADS  CAS  Article  PubMed  Google Scholar 

  40. 40.

    Qu, D. et al. Ablation of doublecortin-like kinase 1 in the colonic epithelium exacerbates dextran sulfate sodium-induced colitis. PLoS ONR 10, e0134212 (2015).

    Article  CAS  Google Scholar 

  41. 41.

    Lopetuso, L. R. et al. IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. Proc. Natl Acad. Sci. USA 115, E9362–E9370 (2018).

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Monticelli, L. A. et al. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin–EGFR interactions. Proc. Natl Acad. Sci. USA 112, 10762–10767 (2015).

    ADS  CAS  PubMed  Article  Google Scholar 

  43. 43.

    Gamo, K. et al. Gene signature–based approach identified MEK1/2 as a potential target associated with relapse after anti-TNFα treatment for Crohn’s disease. Inflamm. Bowel Dis. 24, 1251–1265 (2018).

    PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Lahar, N. et al. Intestinal subepithelial myofibroblasts support in vitro and in vivo growth of human small intestinal epithelium. PLoS ONE 6, e26898 (2011).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Lei, N. Y. et al. Intestinal subepithelial myofibroblasts support the growth of intestinal epithelial stem cells. PLoS ONE 9, e84651 (2014).

    ADS  PubMed  PubMed Central  Article  CAS  Google Scholar 

  46. 46.

    Barker, N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. Nat. Rev. Mol. Cell Biol. 15, 19–33 (2014).

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Zhu, P. et al. IL-13 secreted by ILC2s promotes the self-renewal of intestinal stem cells through circular RNA circPan3. Nat. Immunol. 20, 183–194 (2019).

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Gilbert, S. et al. Activated STAT5 confers resistance to intestinal injury by increasing intestinal stem cell proliferation and regeneration. Stem Cell Rep. 4, 209–225 (2015).

    CAS  Article  Google Scholar 

  49. 49.

    Schumacher, M. A., Danopoulos, S., Alam, D. Al & Frey, M. R. Growth Factors in the Intestinal Tract. In Physiology of the Gastrointestinal Tract (Elsevier Inc., 2018).

  50. 50.

    Wang, Q., Wang, X., Hernandez, A., Kim, S. & Evers, B. M. Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation. Gastroenterology 120, 1381–1392 (2001).

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Jardé, T. et al. Mesenchymal niche-derived neuregulin-1 drives intestinal stem cell proliferation and regeneration of damaged epithelium. Cell Stem Cell 27, 646–662 (2020).

  52. 52.

    Middelhoff, M. et al. Dclk1-expressing tuft cells: critical modulators of the intestinal niche? Am. J. Physiol. Liver Physiol. 313, G285–G299 (2017).

    CAS  Article  Google Scholar 

  53. 53.

    Rosen, M. J. et al. Mucosal expression of type 2 and type 17 immune response genes distinguishes ulcerative colitis from colon-only Crohn’s disease in treatment-naive pediatric patients. Gastroenterology 152, 1345–1357 (2017).

  54. 54.

    He, Z. et al. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc Min/+ mice. Sci. Rep. 7, 5520 (2017).

    ADS  PubMed  PubMed Central  Article  CAS  Google Scholar 

  55. 55.

    Moussion, C., Ortega, N. & Girard, J.-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘Alarmin’? PLoS ONE 3, e3331 (2008).

    ADS  PubMed  PubMed Central  Article  CAS  Google Scholar 

  56. 56.

    Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564–568 (2014).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Cayrol, C. & Girard, J.-P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr. Opin. Immunol. 31, 31–37 (2014).

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Pastorelli, L. et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl Acad.Sci. USA 107, 8017–8022 (2010).

    ADS  CAS  PubMed  Article  Google Scholar 

  59. 59.

    Sedhom, M. A. K. et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62, 1714–1723 (2013).

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Groß, P., Doser, K., Falk, W., Obermeier, F. & Hofmann, C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm. Bowel Dis. 18, 1900–1909 (2012).

    Article  Google Scholar 

  61. 61.

    Lito, P., Mets, B. D., Appledorn, D. M., Maher, V. M. & McCormick, J. J. Sprouty 2 regulates DNA damage-induced apoptosis in ras-transformed human fibroblasts. J. Biol. Chem. 284, 848–854 (2009).

  62. 62.

    Spooner, C. J. et al. Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat. Immunol. 14, 1229–1236 (2013).

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Mahapatro, M. et al. Programming of intestinal epithelial differentiation by IL-33 derived from pericryptal fibroblasts in response to systemic infection. Cell Rep. 15, 1743–1756 (2016).

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Tian, H. et al. Opposing activities of Notch and Wnt signaling regulate intestinal stem cells and gut homeostasis. Cell Rep. 11, 33–42 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Han, L. et al. Interleukin-33 promotes inflammation-induced lymphangiogenesis via ST2/TRAF6-mediated Akt/eNOS/NO signalling pathway. Sci. Rep. 7, 10602 (2017).

    ADS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Ivanov, V. N. et al. Radiation-induced bystander signaling pathways in human fibroblasts: a role for interleukin-33 in the signal transmission. Cell. Signal. 22, 1076–1087 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67.

    Khan, W. I. et al. Stat6 dependent goblet cell hyperplasia during intestinal nematode infection. Parasite Immunol. 23, 39–42 (2001).

  68. 68.

    Elliott, D. E. et al. Heligmosomoides polygyrus inhibits established colitis in IL-10-deficient mice. Eur. J. Immunol. 34, 2690–2698 (2004).

  69. 69.

    Nusse, Y. M. et al. Parasitic helminths induce fetal-like reversion in the intestinal stem cell niche. Nature 559, 109–113 (2018).

  70. 70.

    Waddell, A. et al. IL-33 signaling protects from murine oxazolone colitis by supporting intestinal epithelial function. Inflamm. Bowel Dis. 21, 2737–2746 (2015).

    PubMed  PubMed Central  Article  Google Scholar 

  71. 71.

    El Marjou, F. et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186–193 (2004).

  72. 72.

    Schumacher, M. A. et al. ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation. Cell Death Dis. 8, e2622 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  73. 73.

    Mahe, M. M. et al. Establishment of gastrointestinal epithelial organoids. Curr. Protoc. Mouse Biol. 3, 217–240 (2013).

    PubMed  PubMed Central  Article  Google Scholar 

  74. 74.

    Mahe, M. M., Sundaram, N., Watson, C. L., Shroyer, N. F. & Helmrath, M. A. Establishment of human epithelial enteroids and colonoids from whole tissue and biopsy. J. Vis. Exp. 97, e52483 (2015).

  75. 75.

    Bernard, J. K., McCann, S. P., Bhardwaj, V., Washington, M. K. & Frey, M. R. Neuregulin-4 is a survival factor for colon epithelial cells both in culture and in vivo. J. Biol. Chem. 287, 39850–39858 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76.

    Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525–527 (2016).

    CAS  PubMed  Article  Google Scholar 

  77. 77.

    Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH grants R01DK095004 and R01DK119694 (M.R.F.) and R01DK117119 (M.J.R.), a Research Fellowship Award (A.W.) and a Career Development Award from the Crohn’s and Colitis Foundation (M.A.S.), and funding from CURE for IBD. We thank Britany Hansten for Gata3 immunofluorescence staining and The Saban Research Institute Cellular Imaging core for confocal imaging assistance.

Author information

Affiliations

Authors

Contributions

M.A.S. conceived and designed experiments, performed experiments, analysis/interpretation of data, and wrote the manuscript. J.J.H., C.Y.U., K.L.A., D.A., K.K., J.K.B., and E.B.B. performed experiments, analyzed data, and revised manuscript. A.W., S.G., and K.M.M. performed experiments and revised manuscript. M.K.W. analyzed data and revised manuscript. T.C.G. and D.W. conceived experiments and revised manuscript. M.J.R. conceived and designed experiments, and revised manuscript. M.R.F. study supervision, obtained funding, performed experiments, conceived and designed experiments, analysis/interpretation of data, and wrote manuscript.

Corresponding author

Correspondence to Mark R. Frey.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Source data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schumacher, M.A., Hsieh, J.J., Liu, C.Y. et al. Sprouty2 limits intestinal tuft and goblet cell numbers through GSK3β-mediated restriction of epithelial IL-33. Nat Commun 12, 836 (2021). https://doi.org/10.1038/s41467-021-21113-7

Download citation

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing